Keyphrases
Solid Tumors
100%
Entrectinib
100%
Duration of Response
100%
NTRK Fusion
100%
Confidence Interval
80%
Objective Response Rate
60%
Blinded Independent Central Review
40%
Treatment-related Adverse Events
40%
Histology
20%
Phase II Trial
20%
Pediatric Patients
20%
Clinical Follow-up
20%
Adult Patients
20%
Locally Advanced
20%
Central Nervous System
20%
Safety Profile
20%
Clinical Experience
20%
Long Follow-up
20%
Response Rate
20%
Tumor Subtype
20%
Active Treatment
20%
Progression-free Survival
20%
Partial Response
20%
Clinical Cutoff
20%
Systemic Response
20%
Unmet Needs
20%
Dose Adjustment
20%
Nervous System Diseases
20%
Median Progression-free Survival
20%
Tropomyosin Receptor Kinase B
20%
ROS1
20%
Intracranial Response
20%
Medicine and Dentistry
Solid Malignant Neoplasm
100%
Entrectinib
100%
Adverse Event
40%
Progression Free Survival
40%
Pediatrics Patient
20%
Neoplasm
20%
Central Nervous System
20%
Central Nervous System Disease
20%
Tropomyosin Receptor Kinase B
20%
Active Treatment
20%
Pharmacology, Toxicology and Pharmaceutical Science
Entrectinib
100%
Solid Malignant Neoplasm
100%
Adverse Event
40%
Progression Free Survival
40%
Tropomyosin
20%
Receptor
20%
Central Nervous System Disease
20%
Neoplasm
20%